IL-8 RECEPTOR ANTAGONISTS

Abstract: This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

Description: IL-8 RECEPTOR ANTAGONISTS FIELD OF THE INVENTION This invention relates to a novel group of phenyl urea compounds, processes for the preparation thereof, the use thereof in treating IL-8. GROα. GROβ, GROγ, ENA-78 and NAP-2 mediated diseases and pharmaceutical compositions for use in such therapy BACKGROUND OF THE INVENTION Many different names have been applied to Interleukιn-8 (IL-8), such as neutrophil attractant/activation protein- 1 (NAP- 1 ), monocyte derived neutrophil chemotactic factor (MDNCF). neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor Interleukιn-8 is a chemoattractant for neutrophils, basophils and a subset of T-cells It is produced by a majority of nucleated cells including macrophages. fibroblasts, endothelial and epithelial cells exposed to TNF, IL-la, IL-lb or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP M Baggiohni et al. J Clin Invest 84 1045 ( 1989), J Schroder et al, J Immunol 739. 3474 ( 1987) and J Immunol 144. 2223 ( 1990) , Stπeter, et al, Science 243. 1467 ( 1989) and J Biol Chem 264. 10621 ( 1989), Cassatella et al J Immunol 148. 3216 ( 1992) GROα, GROβ, GROγ. and NAP-2 also belong to the chemokine α family Like IL-8 these chemokines have also been referred to by different names For instance GROα, β, γ have been referred to as MGSAα, β and γ respectively (Melanoma Growth Stimulating Activity), see Richmond et al, J Cell Physiology 129, 375 (1986) and Chang et al. J Immunol 148. 451 ( 1992) All of the chemokines of the a-family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor IL-8, GROα, GROβ, GROγ, and NAP-2 stimulate a number of functions in vitro They have all been shown to have chemoattractant properties for neutrophils. while IL-8 and GROa have demonstrated T-lymphocytes, and basophiles chemotactic activity In addition IL-8 can induce histamine release from basophils from both normal and atopic individuals GRO-α and IL-8 can in addition, induce lysozomal enzyme release and respiratory burst from neutrophils IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis This may contribute to increased adhesion of the neutrophils to vascular endothehal cells Many known diseases are characterized by massive neutrophil infiltration As IL-8 GROα. GROβ, GROγ and NAP-2 promote the accumulation and activation of neutrophils. these chemokines have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis. Baggio ni et al, FEBS Lett 307. 97 ( 1992), Miller et al, Cπt Rev Immunol 12. 17 ( 1992), Oppenheim et al, Annu Rev Immunol 9. 617 ( 1991 ). Seitz et al , J Clin Invest 87, 463 ( 1991 ), Miller et al , Am Rev Respir Pis 146. 427 ( 1992), Donnely et al., Lancet 341. 643 ( 1993) In addition the ELR chemokines (those containing the ammo acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis Stπeter et al. Science 258. 1798 ( 1992) In vitro, IL-8. GROα. GROβ, GROγ and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-hnked family, in particular by binding to IL-8 receptors, most notably the B-receptor Thomas et al , J Biol Chem 266. 14839 ( 1991 ). and Holmes et al . Science 253. 1278 ( 1991 ) The development of non-peptide small molecule antagonists for members of this receptor family has precedent For a review see R Freidinger in Progress in Drug Research. Vol 40, pp 33-98, Birkhauser Verlag, Basel 1993 Hence, the IL-8 receptor represents a promising target for the development of novel anti- lnflammatory agents Two high affinity human IL-8 receptors (77% homology) have been characterized IL-8Ra. which binds only IL-8 with high affinity, and IL-8Rb, which has high affinity for IL-8 as well as for GROα. GROβ GROγ and NAP-2 See Holmes et al . supra. Murphy et al , Science 253. 1280 ( 1991 ), Lee et al , J Biol Chem 267. 16283 ( 1992), LaRosa et al . J Biol Chem 267. 25402 ( 1992). and Gayle et al , J. Biol Chem. 268. 7283 ( 1993) There remains a need for treatment, in this field, for compounds which are capable of binding to the IL-8 a or b receptor Therefore, conditions associated with an increase in IL-8 production (which is responsible for chemotaxis of neutrophil and T-cells subsets into the inflammatory site) would benefit by compounds which are inhibitors of IL-8 receptor binding SUMMARY OF THE INVENTION δϋBSmυTE SHEET (RULE 26) This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (I), or (II). or a pharmaceutically acceptable salt thereof. In particular the chemokine is IL-8. This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), or Formula (II). This invention also relates to the novel compounds of Formula (I), represented by the structure: W— N N — .CR R R " H (I) wherein X is oxygen or sulfur. R is C(O)NHS(O) m R b . R " is independently selected f rom hydrogen, halogen, nitro. cyano; halosubstituted Ci - io alkyl. C ] _ ι o alkyl; C2- 10 alkenyl; C ] _ ι o aikoxy. halosubstituted Cj - io alkoxy: azide; (CRgRg)q S(O) t R4; hydroxy. hydroxv C ι _4alkyl, (CRgRg)q OR4; aryl; aryl -4 alkyl; aryloxy; aryl C * _4 alkyloxy; heteroaryl, heteroarylalkyl, heterocyclic. heterocyclic C ] _4alkyl. heteroaryl C ] -4 alkyloxy; aryl C2- 10 alkenyl; heteroaryl C2- 10 alkenyl. heterocyclic C2-10 alkenyl; (CR 8 R 8 )qNR4R5- - 10 alkenyl C(0 ) NR4R. . ( CR 8 R 8 ) q C(O ) NR4R5- (CR 8 R 8 )q C(0)NR 4 R 10, S(O)3R8; (CRgR 8 )qC( 0)R 1 1 , C 2 - 10 alkenylC(O)R \ \ . Ci- \ 0alkenylC(O)OR 1 1 , (CRgRg )qC(0)OR 12, (CR 8 R 8 )qOC(0)R ι ] ; (CR 8 R 8 )qNR4C(O)R ι 1 , (CR 8 Rg)qNHS(O) 2 Ri9; (CR 8 R 8 )q S(O) 2 NR 4 R 5 ; (CR 8 R 8 )qC(NR 4 )NR 4 R 5 . (CR 8 Rg)qNR4C(NR5)R j ■ ; or two R * moieties together may form O-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl, and heterocyclic containing moieite.s may be optionally substituted; q is 0, or an integer having a value of 1 to 10, t is 0, or an integer having a value of 1 or 2; s is an integer having a value of 1 to 3; v is 0 or an integer having a value of 1 to 4; m is an integer having a value of 1 to 3; n is an integer having a value of 1 to 3; R4 and R5 are independently hydrogen, optionally substituted C1.4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl Ci -4alkyl, heterocyclic, heterocyclic C 1-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S; Y is independently selected from hydrogen; halogen; nitro: cyano: halosubstituted Cj- io alkyl; Ci- io alkyl; C2- 10 alkenyl; Ci- io alkoxy; halosubstituted C i- 10 alkoxy; azide; (CR 8 R 8 )q S(O)tR4; hydroxy; hydroxyC i -4alkyl; aryl; aryl C i-4 alkyl; aryloxy; arylC i -4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl C * _4 alkyloxy; heterocyclic, heterocyclic C i -4alkyl; aryl C2- 10 alkenyl; heteroaryl C2- 10 alkenyl; heterocyclic C2- 10 alkenyl; (CR 8 R )q NR4R5; C2- 10 alkenyl C(O)NR4R5; (CR 8 R 8 )q C(O)NR4R5; (CR 8 R 8 )q C(O)NR4R l0: S(0)3R8; (CR 8 R 8 )q C(0)R 1 1 ; C2- IO alkenyl C(O)R 1 1 ; C2- 10 alkenyl C(O)OR 1 1 ; C(O)R i i ; (CR 8 R 8 )q C(O)OR * ; (CR 8 R 8 )q OC(O) Rl l ; (CR 8 R 8 )q NR4C(O)Rι 1 , (CR 8 R 8 )q NHS(O) 2 Rcj; (CR 8 R 8 )q S(0) 2 NR 4 R5: (CR 8 R 8 )qC(NR4)NR 4 R 5 : (CR 8 R 8 )q NR C(NR 5 )R ι • or two Y moieties together may form O-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring; wherein the aryl, heteroaryl, and heterocyclic containing moieites may be optionally substituted; R and R7 are independently hydrogen or a C 1 -4 alkyl group; or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R 8 is independently selected from hydrogen or C | -4 alkyl; RlO is C i- io alkyl C(O)2R8; Rl 1 is hydrogen, optionally substituted C 1-4 alkyl, optionally substituted aryl, optionally substituted aryl C * -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC ] -4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicCi-4alkyl; R l 2 is hydrogen, C i- io alkyl, optionally substituted aryl or optionally substituted arylalkyl; Rl3 and R14 are independently hydrogen, optionally substituted C i-4 alkyl or one of Rj3 and R14 may be optionally substituted aryl; Rfc, is NR^R , alkyl, aryl, aryl C * _4 alkyl, aryl C2_4 alkenyl, heteroaryl, heteroaryl C * _4 alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocyclic C j _4 alkyl, heterocyclic C2-4 alkenyl, or camphor, wherein the arlkyl, aryl, heteroaryl, and heterocyclic ring containing groups may be optionally substituted; R f j is NR6R7, alkyl, arylC j.4 alkyl, arylC 2-4 alkenyl, heteroaryl, hetroarylCι_4alkyl, heteroarylC2-4 alkenyl, heterocyclic, or heterocyclicCι.4 alkyl, and wherein the alkyl, aryl, heteroaryl, and heterocyclic ring containing groups may be optionally substituted; Rl9 is suitably C 1-4 alkyl. aryl, aryl Cι_4alkyl, heteroaryl, heteroarylCι_4alkyl, heterocyclic, or heterocyclιcC]-4alkyl, and wherein the all of these moieties may be optionally substituted; R20 is W- , the E containing ring is optionally selected from the asteπx * denoting point of attachment of the ring; the E' containing ring is optionally selected from SUBSTITUTE SHEET (RULE __t)j ring, or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION The compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokines which bind to the IL-8 a and b receptors Chemokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section. Another aspect of this invention also relates to the novel compounds of Formula (II). represented by the structure W — N N— (CR 13 R, 4 )v -R H 20 (I) wherein X is oxygen or sulfur; Rl is independently selected from hydrogen; halogen; nitro, cyano; halosubstituted Cj-io alkyl; Ci-io alkyl; C2-10 alkenyl; Ci-io alkoxy, halosubstituted Cj-io alkoxy, azide; (CR 8 R 8 )q S(O) t R 4 ; hydroxy; hydroxy C]-4alkyl; (CR 8 R )q OR4; aryl; aryl Ci-4 alkyl; aryloxy; aryl -4 alkyloxy: heteroaryl; heteroarylalkyl; heterocyclic, heterocyclic Cj-4alkyl, heteroaryl C\ .4 alkyloxy; aryl C2-10 alkenyl; heteroaryl C2-10 alkenyl; heterocyclic C2-10 alkenyl; (CR 8 R 8 )qNR4R5; C2-10 alkenyl C(O)NR4R5, (CR 8 R 8 )q C(O)NR4R5; (CR 8 R 8 )q C(O)NR4Rlθ; S(O) 3 R8i (CR 8 R 8 )qC(O)Rι 1; C 2 -10 alkenylC(O)R n , C2- 10alkenylC(O)OR ι ι ; (CR 8 R 8 )qC(O)ORi 2; (CR 8 R 8 )qOC(O)R ι i ; (CR 8 R 8 )qNR4C(O)R ι i , (CR 8 R 8 )qNHS ( O) 2 Ri9; (CR 8 R 8 )q S(0) 2 NR 4 R 5 . (CR 8 R 8 )qC(NR 4 )NR4R5, (CR 8 R 8 )qNR4C(NR5)R j j , or two R l moieties together may form O-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring; and wherein the aryl, heteroaryl, and heterocyclic containing moieites may be optionally substituted; q is 0, or an integer having a value of 1 to 10: t is 0, or an integer having a value of 1 or 2; s is an integer having a value of 1 to 3. v is 0 or an integer having a value of 1 to 4; m is an integer having a value of 1 to 3; n is an integer having a value of 1 to 3; R4 and R5 are independently hydrogen, optionally substituted C j -4 alkyl, optionally substituted aryl. optionally substituted aryl C ] _4alkyl. optionally substituted heteroaryl, optionally substituted heteroaryl C ι _4alkyl, heterocyclic, heterocyclic C | .4 alkyl. or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S. R and R7 are independently hydrogen or a C ] -4 alkyl group; or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, R is independently selected from hydrogen or C i -4 alkyl, R lO is C i - io alkyl C(O)2R8; R l 1 is hydrogen, optionally substituted C [ _4 alkyl, optionally substituted aryl, optionally substituted aryl C ι _4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclicC i -4alkyl. Rl2 is hydrogen, C ι _ 10 alkyl, optionally substituted aryl or optionally substituted arylalkyl; Rl3 and R14 are independently hydrogen, optionally substituted C 1 -4 alkyl or one of R13 and R 14 may be optionally substituted aryl; R is NR6R7, alkyl, aryl, aryl C * _4 alkyl, aryl C2-4 alkenyl, heteroaryl, heteroaryl Cι_4 alkyl, heteroarylC2_4 alkenyl, heterocyclic. heterocyclic C ι _4 alkyl, heterocyclic C2-4 alkenyl, or camphor, wherein the arlkyl. aryl. heteroaryl, and heterocyclic ring containing groups may be optionally substituted; R]9 is suitably Ci-4 alkyl, aryl, aryl Ci-4alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclic, or heterocyclιcCi-4alkyI, and wherein the all of these moieties may be optionally substituted; R20 is an optionally substituted heteroaryl, optionally substituted C5_ cycloalkyl, optionally substituted C μ j ø alkyl, optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl; the E containing ring is optionally selected from the asteπx * denoting point of attachment of the ring; the E' containing ring is optionally selected from the ring, or a pharmaceutically acceptable salt thereof. In compounds of Formula (I) and (II), suitably W is Suitably, the E containing ring is optionally selected from The E containing ring, denoted by its point ot attachment through the asteπx (*), may optionally be present. If not present then the ring is a phenyl moiety which is substituted by the (R ] ) m terms as shown. The E ring may be substituted by a (R l ) m moiety in any ring, saturated or unsaturated. and is shown for purposes herein substituted only in the unsaturated πng(s). In compounds of Formula (I) and (II), R is suitably a functional moiety which provides an lonizable hydrogen having a pKa of 10 or less, preferably from about 3 to 9, more preferably from about 3 to 7 This R group is the moiety C ( 0 ) NHS ( 0) Rb- Suitably, R * -, is a NR5R7, alkyl. aryl, aryl C [ _4 alkyl, aryl C2-4 alkenyl, heteroaryl, heteroaryl C j_4 alkyl, heteroarylC2-4 alkenyl, heterocyclic. heterocyclic Cι_4 alkyl. a heterocyclic C2-4 alkenyl moiety, or camphor, all of which groups may be optionally substituted one to three times independently by halogen; nitro; halosubstituted C1.4 alkyl, such as CF3; C1.4 alkyl, such as methyl; C ] _4 alkoxy, such as methoxy; aryl; heteroaryl; heterocyclic: NR9C(O)R a ; O^RgR , S(O)3H, S(0) m 'R a (wherein m' is 0, 1 or 2), or C(O)OC j _4 alkyl. When Rtø is an aryl or arylalkyl, preferably it is an optionally substituted phenyl, benzyl, or styryl. When Rfc is a heteroaryl, as defined herein, it is preferably an optionally substituted thiazole, optionally substituted thienyl, optionally substituted quinolinyl or isoquinolyl ring, or pyridyl ring. - 9- SUBST1TUTE SHEET (RULE 26) Suitably R a is an alkyl. aryl. arylCi-4alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclic, or a heterocyclic Ci-4alkyl moiety, all of which may be optionally substituted, as defined herein below Suitably, Rό and R7 are independently hydrogen or a C1-4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur This heteroπng may be optionally substituted as defined herein. R9 is hydrogen or a C [ _4 alkyl, preferably hydrogen. Suitably, when the substituent group on the R5 moiety is NR9 O)R a , then R a is preferably an alkyl group, such as methyl. In compounds of Formula (I) and (II), suitably Rl is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted Cj-io alkyl, such as CF3; Ci-io alkyl. such as methyl, ethyl, isopropyl, or n-propyl; C2-10 alkenyl; Ci-io alkoxy. such as methoxy, orethoxy; halosubstituted Ci-io alkoxy, such as tπfluoromethoxy; azide; (CR R )q S(O) t R4, wherein t is 0, 1 or 2: hydroxy; hydroxy Ci-4alkyl, such as methanoi or ethanol; (CR R 8 )q OR4; aryl, such as phenyl or naphthyl: aryl Ci-4 alkyl, such as benzyl; aryloxy. such as phenoxy; aryl Ci-4 alkyloxy. such as benzyloxy; heteroaryl; heteroarylalkyl; heteroaryl Cj-4 alkyloxy: aryl C2-10 alkenyl ; heteroaryl C2-I0 alkenyl: heterocychc C2-10 alkenyl; (CR 8 R 8 )qNR4R5; C2-10 alkenyl C(O)NR4R5 (CR R )q C(O)NR4R5 * (CR 8 R 8 )q C(O)NR4Rl0; S(0)3H: S(0)3R ; (CR 8 R 8 )qC(0)Ri l, C2-10 alkenylC(O)Ri 1; C2- 10 alkenyIC(O)OR 11 ; (CR 8 R 8 )q C(0)OR 1 Ύ. (CR 8 R 8 )qOC(0)R 1 \ , (CR 8 R 8 )qNR4C(O)Rl 1, (CR 8 R 8 )q NHS(O) 2 Ri9, (CR 8 R 8 )qS(O) 2 NR 4 R 5 ; (CR 8 R 8 )qC(NR 4 )NR 4 R 5 ; (CR 8 R 8 )qNR 4 C(NR 5 )Rι - , or two Rl moieties together may form 0-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring. The aryl, heteroaryl, and heterocyclic containing moieties may all be optionally substituted as defined herein below. Suitably, s is an integer having a value of 1 to 3. Suitably, q is 0, or an integer having a value of 1 to 10. When R l forms a dioxy bridge, s is preferably 1 When Rl forms an additional unsaturated ring, it is preferably 6 membered resulting in a naphthylene ring system This naphthylene ring may be substituted independently, 1 to 3 times by the other R { moieties as defined above In compounds of Formula (I) and (II), suitably, R4 and R5 are independently hydrogen, optionally substituted C 1.4 alkyl, optionally substituted aryl, optionally substituted aryl C ] -4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C i -.4alk.yl, heterocyclic, heterocyc cC 1.4 alkyl, or R4 and R5 together with the nitrogen to hich they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S In compounds of Formula (I) and (II), R is suitably independently selected from hydrogen or C 1.4 alkyl In compounds of Formula (I) and (II), R j θ i suitably C j - 10 alkyl C(O)2R8. such as CH2 O)2H or CH2C(0)2CH3 In compounds ol Formula (I) and (II), R l l is suitably hydrogen, C ι _4 alkyl, aryl, aryl C i -4 alkyl, heteroaryl, heteroaryl C ι _4alkyl. heterocyclic. or heterocyclic C i -4alkyl In compounds of Formula (I) and (II), R 12 is suitably hydrogen, C J . J O alkyl, optionally substituted aryl or optionally substituted arylalkyl In compounds of Formula (I) and (II), R ] 9 is C 1 -4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC i -4alkyl. heterocyclic, or heterocychcC i-4alkyl, wherein the all of these moieties may be optionally substituted In compounds of Formula (I) and (II), preferably R i is halogen, cyano, nitro, CF3, C(O)NR4R5, alkenyl C(O)NR4R5, C(O) R4 IO. alkenyl C(O)OR i 2, heteroaryl, heteroarylalkyl , heteroaryl alkenyl, 01 S(O)NR4R5; preferably R4 and R5 are both hydrogen or one is phenyl. A preferred ring substitution for R ] is in the 4-posιtion of the phenyl ring. In compounds of Formula (I) and (II),when R is OH, SH or NSO2Rb than Rl is preferably substituted in the 3-posιtιon, or 4- position, or is di substituted in - 11- 8UBSTJTUTE SHEET (RULE 26 , the 3.4- position. The substituent group is preferably an electron withdrawing moiety. Further, it is preferable when R is OH. SH or NSO2Rb than Ri is a nitro, halogen, cyano, trifluoromethyl. or C(O)NR4R5 group. When R is a carboxylic acid, Rl is preferably hydrogen; or Rj is preferably substituted in the 4-posιtιon, more preferably substituted by trifluoromethyl or chloro. In compounds of Formula (I) and (II), suitably R13 and R 14 are independently hydrogen, optionally substituted C i -4 alkyl which may be straight or branched as defined herein, or one of R13 and R14 are an optionally substituted aryl; v is 0. or an integer having a value of 1 to 4. When R i3 or R 14 are an optionally substituted alkyl, the alkyl moiety may be substituted one to three times independently by halogen; halosubstituted Ci-4 alkyl such as trifluromethyl: hydroxy; hydroxy Ci_4alkyl, C j -4 alkoxy; such as methoxy, or ethoxy, halosubstituted C i-io alkoxy, S(O)tR4; aryl: NR4R5; NHC(O)R4; C(O)NR4R5. or C(O)OR 8 . In compounds of Formula (I), suitably, Y is independently selected from hydrogen: halogen; nitro; cyano; halosubstituted Ci-io alkyl; Ci- io alkyl; C2-10 alkenyl; C μio alkoxy; halosubstituted Ci- io alkoxy; azide; (CR R 8 )q S(O)tR4; (CR 8 R 8 )q OR4; hydroxy; hydroxyCi-4alkyl; aryl; aryl C j -4 alkyl; aryloxy; arylCi-4 alkyloxy; heteroaryl, heteroarylalkyl; heteroaryl C i-4 alkyloxy; heterocyclic, heterocyclic Ci-4alkyl; aryl C2-10 alkenyl; heteroaryl C2-10 alkenyl; heterocychcC2- 10 alkenyl; (CR R 8 )qNR4R5, C2- 10 alkenylC(O)NR4R5; (CR 8 R 8 )qC(O ) NR4R5: ( CR 8 R 8 )q C(O)NR4Rl0; S(O) 3 H, S(O)3R8; (CR 8 R 8 )q C(O)Ri j ; C2-10 alkenyl C(O)R ι 1 ; C2- 10 alkenyl C(0)ORi 1 ; (CR 8 R 8 )q C(O)ORi2; (CR 8 R 8 )q OC(O) Rl l ; (CR 8 R 8 )q NR 4 C(O)Rι 1 ; (CR 8 R 8 )qNHS(O) 2 Rd; (CR 8 R 8 )qS(O)2NR 4 R 5 ; (CR 8 R 8 )qC(NR4,NR 4 R 5 ; (CR R 8 )qNR4C(NR5)Rι 1 ; or two Y moieties together may form 0-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring. Additionally all of the various aryl, heteroaryl and heterocyclic groups noted above, as well as the R4, R5 and Ri 1 substituent groups, may be optionally substituted as defined herein in the specification below. When Y forms a dioxybridge, s is preferably 1. When Y forms an additional saturated or unsaturated ring, it is preferably 6 membered unstaturated ring resulting in a naphthylene ring system. These rings may be substituted 1 to 3 times by additional (Y)n moieties as defined above. - 12- 8UBSTITUTE SHEET (RULE 26) Suitably, Rj is a NRgR7, alkyl, aryl Cι _4 alklyl, arylC 2-4 alkenyl, heteroaryl, hetroaryl-C^alkyl, heteroarylC2-4 alkenyl, heterocyclic, heterocychcC].4 alkyl, or heterocyclic C 2-4 alkenyl moiety, wherein the alkyl, aryl, heteroaryl, and heterocyclic containing moieties noted above may all be optionally substituted as defined herein. Y is preferably a halogen, C ι_4 alkoxy, optionally substituted aryl, optionally substituted aryloxy or arylalkoxy, methylene dioxy, NR4R5, thio Ci-4alkyl, thioaryl, halosubstituted alkoxy, optionally substituted Cj-4 alkyl, or hydroxy alkyl Y is more preferably mono- or di-substituted halogen, mono- or di- substituted alkoxy, methylenedioxy, aryl, or alkyl, more preferably these groups are mono or di-substituted in the 2'- position or 2'-, 3'-posιtιon While Y may be substituted in any of the 5 ring positions, preferably when R is OH, SH, or NSO2Rb< Y i preferably mono-substituted in the 2'-posιtιon or 3'- position. with the 4 - preferably being unsubstituted If the ring is disubstituted, when R is OH, SH, or NSO2Rb, substituents are preferably in the 2' or 3' position of a monocyclic ring While both R \ and Y can both be hydrogen, it is prefered that at least one of the rings be substituted, preferably both rings are at least mono- substituted, i.e., n a d m are each equal to 1 or more Y is more preferably a mono-substituted halogen, disubstituted halogen, mono-substituted alkoxy, disubstituted alkoxy, methylenedioxy, aryl, or alkyl, preferably these groups are substituted m the 2'- position or 2'-, 3 -position In compounds of Formula (I) and (II), X is suitably oxygen or sulfur, preferably oxygen. In compounds of Formula (I), R20 i W * and Wj is suitably, 13- 8UBSTITUTE SHEET (RULE 26) Suitably, the E' containing ring is optionally selected from The E' containing ring, denoted by its point of attachment through the asterix (*), may optionally be present. If not present the ring is a phenyl moiety which is substituted by the Y terms as shown. The E ring may be substituted by a (Y) n moiety in any ring, saturated or unsaturated, and is shown for purposes herein substituted only in the unsaturated πng(s). In compounds of Formula (II), Rir j is an optionally substituted heteroaryl, an optionally substituted C5_ cycloalkyl. an optionally substituted C J ' J O alkyl, an optionally substituted C2- 10 alkenyl, or an optionally substituted C2- 10 alkynyl. When R20 ιs an optionally substituted C5_ 8 cycloalkyl ring, the ring may be substituted by (Y) n as defined above for Formula (I) When R20 i an optionally substituted C \ . \Q alkyl. an optionally substituted C2-10 alkenyl, or an optionally substituted C2- 10 alkynyl, these moieties may be optionally substituted one or more times independently by halogen, nitro; cyano; halosubstituted C ]-io alkyl, such as trifluoromethyl, C ] _ 10 alkoxy: halosubstituted Ci- 10 alkoxy; S(O)tR4; hydroxy; hydroxy C i -4alkyl;; aryloxy; arylC ] -4 alkyloxy; heteroaryloxy; heteroaryl C i -4 alkyloxy: heterocyclic. heterocyclic C ] -4alkyl; heterocychcoxy; heterocyclic C ι_4 alkyloxy; NR4R5; C(0)NR4R5. C(O)NR4Rιo; S(0)3H; S(O)3R8; C(O)R ι 1 ; C(O)ORi2; OC(O) Rj 1 ; or NR4C(0)Rj \ . When R20 is an optionally substituted C2- 10 alkenyl, or an optionally substituted C2-10 alkynyl these moieties may also, in addition to those moieties noted above, be optionally substituted with aryl, aryl Cj-4 alkyl, heteroaryl, and heteroarylalkyl. In compounds of Formula (II), when R20 1S heteroaryl (HET) ring, it is suitably a heteroaryl ring or ring system. If the HET moiety is a multi ring system, the ring containing the heteroatom does not need to be directly attached to the urea moiety. All the rings in this ring system may be optionally substituted as defined herein. Preferably the HET moiety is a pyridyl, which may be 2-. 3- or 4-pyridyl. If the ring is a multi system ring it is preferably benzimidazole, dibenzothiophene, - 14- SUBSTTTUTE SHEET (RULE 28) or an indoie ring. Other heterocyclic rings of interest include, but are not limited to thiophene, furan, pyπmidme, pyrrole, pyrazole, quinohne. isoquinoline, quinazohnyl, pyπdine. oxazole, thiazole, thiadiazole, tπazole. imidazole, or benzimidazole In compounds of Formula (II), the HET ring may be optionally substituted by ( Y) n , as defined above for compounds of Formula (I) In compounds of Formula (II), R20 is preferably optionally substituted pyπdyl, allyl. J . J Q alkyl. ethoxy carbonyl ethyl, dimethylacetal. 2-methoxy isopropyl. or 2-methoxy ethyl As used herein 'optionally substituted" unless specifically defined shall mean such groups as halogen, such as cyano, nitro, fluorine, chlorine, bromine or iodine, hydroxy. hvdroxv substituted C i- ioalkyi, C \ . \ o alkoxy, such as methoxy or ethoxy, S(O)m' C ι _ κ) alkyl. wherein m' is 0, 1 or 2. such as methyl thio, methyl sulfinyl or methyl sultonyl. amino, mono & di-substituted amino, such as in the NR4R5 group. NHC(0)R4. C(0)NR4R5, C(O)OR * - . S(0)2NR4Rs, NHS(O)2R21 , C] _ ιo alkyl, such as methyl, ethyl, propyl, isopropyl. or t-butyl, halosubstituted Ci- 10 alkyl, such CF3. an optionally substituted aryl, such as phenyl. or an optionally substituted arylalkyl. such as benzyl or phenethyi. optionally substituted heterocyhc, optionally substituted heterocy calkyl, optionally substituted heteroaryl, optionally substituted heteroaryl alkyl, wherein these aryl, hetroaryl. or heterocyclic moieties may themselves be optionally substituted one to two times by halogen; hydroxy, hydroxy substituted alkyl. C ι_ 10 alkoxy, S(O)m'C i - i o alkyl, amino, mono & disubstituted amino. such as in the NR4R5 group. C μ io alkyl, or halosubstituted Cj _ 10 alkyl, such as CF3 R21 is suitably C j -4 alkyl, halosubstituted C | _4 alkyl, aryl. aryl C ] -4aIkyl, heteroaryl, heteroarylCi -4alkyl. heterocyclic, or heterocychcC i-4alkyl Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaπc acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. The following terms, as used herein, refer to- • "halo" - all halogens, that is chloro, fluoro. bromo and lodo. • "C ι_ ιoalkyl" or "alkyl" - both straight and branched chain radicals of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, /i-propyl. wσ-propyl. /.-butyl, sec-b iy\, ιso-buiy\, tert- butyl, «-pentyl and the like • The term "cycloalkyl" is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like. • The term "alkenyl" is used herein at all occurrences to mean straight or branched chain radical of 2- 10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, l -propenyl, 2-propenyl, 2-methyl-l - propenyl, 1 -butenyl. 2-butenyl and the like • "aryl" - phenyl and naphthyl, • "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or "heteroaryl alkyl") - a 5- 10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinohne, isoquinoline, quinazohnyl, pyπdine, pyπmidine, oxazole, thiazole. thiadiazole, tπazole. lmidazole, or benzimidazole • "heterocyclic" (on its own or in any combination, such as heterocyclicalkyl") - a saturated or partially unsaturated 4- 10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S, such as, but not limited to, pyrrohdine, pipeπdine, piperazine, morpho ne, tetrahydropyran, or lmidazohdine • The term "arylalkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean C \ .\o alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated • "sulfinyl" - the oxide S (O) of the corresponding sulfide. the term ' thio ' refers to the sulfide, and the term "sulfonyl" refers to the fully oxidized S(O)2 moiety. • The term "wherein two R] moieties (or two Y moieties) may together form a 5 or 6 membered saturated or unsaturated ring" is used herein to mean the formation of a ring system, such as a napthylene ring system or a phenyl moiety having attached a 6 membered partially unsaturated ring attached, such as a C(> cycloalkenyl, i.e hexene, or a C5 cyloalkenyl moiety, cyclopentene. It is recognized that compounds of the present invention may exist as stereoisomers, regioisomers, or diastereiomers These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms All of these compounds are included within the scope of the present invention METHODS OF PREPARATION The compounds of Formula (I), and (II) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below The synthesis provided for in these Schemes is applicable for the producing compounds of Formula (I), having a variety of different R, R ] , and R20 groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed Once the urea nucleus has been established, further compounds of these formulas may be prepared by applying standard techniques for functional group interconversion, well known in the art While the schemes are shown with compounds only of Formula (I), wherein the R is attached to a phenyl ring, R j , m, and R5, Y, and n are as defined for compounds of Formula (I) and (II), and R20 i noted herein as an optionally substituted phenyl ring, this is merely for illustration purposes only The compounds of Formula (I) and (II) may be prepared by reacting an acid chloride of Formula ( 1 ) with a sulfonamide of Formula (2) 17- SUBST1TUTE SHEET (RULE 26) in a suitable solvent such as dichloromethane to afford an acyl sulfonamide of Formula (3) Reduction of an nitro group in Formula (3) using an appropriate reducing agent such as SnCh or hydrogen with palladium on carbon provides an aniline of Formula (4) Treatment of an aniline of Formula (4) with a compound of Formula (5) in a suitable solvent such as N'.N'-dimethylformamide affords a compound of Formula (I) Alternatively, an acyl sulfonamide of Formula (3 ) could be prepared by reacting a phenol of Formula (6) with tπfluoromethanesulfonic anhydride in a suitable solvent such as dichloromethane to give a tnflate (OTf) of Formula (7) Coupling of " a tπflate of Formula (7) with an sulfonamide of Formula (2) in the presence of carbon monoxide and a palladium catalyst in a suitable solvent such as N',N'-dιmethylformamιde provides a compound of Formula (3). Pharmaceutically acceptable salts of compounds of Formula (I) and (II) may be obtained in known manner, for example by treatment thereof with an appropriate amount of acid or base in the presence of a suitable solvent. In the Examples, all temperatures are in degrees Centigrade (°C). Mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment, unless otherwise indicated. - H-NMR (hereinafter "NMR") spectra were recorded at 250 MHz or 400MHz using a Bruker AM 250 or AM 400 spectrometer, respectively. Multiplicities indicated are s=sιnglet. d=doublet. t=tπplet. q=quartet. m=multιplet and br indicates a broad signal. Sat. indicates a saturated solution, equiv indicates the proportion of a molar equivalent of reagent relative to the principal reactant. Flash chromatography is run over Merck Silica gel 60 (230 - 400 mesh). SYNTHETIC EXAMPLES The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. All temperatures are given in degrees centigrade, all solvents used herein are of the highest available purity and all reactions are run under anhydrous conditions in an argon atmosphere unless otherwise indicated. EXAMPLE 1 N-f3-(4-methylphenyl.sulfonyl)carboxamιdo1-N"-(2-bromophenyl)urea a) Prepraration of 3-Nιtrobenzoyl chloride To a suspension of 3-nitrobenzoic acid (934 mg. 5.64 mmol ) in benzene ( 15 mL) was added oxalyl chloride (0.6 L, 6.77 mmol ) and DMF (7 mL), respectively. The resulting mixture was stirred at room temperature until a clear solution was formed. The solvent was removed under reduced pressure and crude acid chloride was used in the next reaction without further purification. b) Preparation of N-(3-Nitrobenzoyl)-4-methoxybenzenesulfonamide - 19- SUBSTJTUTE SHEET (RULE 26) To a solution of 4-methylbenzenesulfonamιde ( 1 00 g, 5.64 mmol) in THF (15 mL) was added NaH (450 mg, 1 1 28 mmol) at room temperature under argon and the resulting mixture was stirred for 4 h at room temperature. To this solution was added the acid chloride in THF (3 mL). After stirring for 2 h at room temperature, the mixture was poured into aqueous NaOH and washed with 1: 1 EtOAc/hexane (3x100 mL). The aqueous layer was then acidified with 6 N HC1 and extracted with EtOAc (3x50 mL). The combined organic extracts were washed with brine and dried (Na2SO4). Removal of the solvent gave 920 mg (51%) of the title compound MS [M-H) 319. c) Preparation of N-(3-Amιnobenzoyl)-4-methoxybenzenesulfonamιde A mixture of N-(m-Nιtrobenzoyl)-4-methoxyben7enesulfonamιde (920 mg, 2.87 mmol) and 100 mg of 10% Pd/C in ethanol (20 mL) was shaken under H2 (60 Psi) tor 2 days at room temperature After removing the catalyst by filtration, the filtrate was concentrated to afford 430 mg of the title compound which was used in the next reaction without further purification d) Preparation of N-, 3-(4-methylphenylsulfonyi)carboxamιdol-N'-(2- bromopheny 1 )urea To a solution of N-(3-Amιnobenzoyl)-4-methoxybenzenesulfonamιde (430 mg, 1 48 mmol) in DMF (4 mL) was added 2-bromophenyhsocyanιde (293 mg, 1 48 mmol) and the resulting mixture was stirred at 60 °C for 4 h The reaction mixture was then poured into water and and extracted with 1.1 EtOAc/hexane (3x100 mL) The combined organic extracts were washed with brine and dried (Na2SO4) After removing the solvent, the residue was washed with CH CI2 to afford 252 mg of the title compound as a white solid, m.p 192-5 °C. MS [M-HJ 486, - H NMR (DMSO- d 6 , 400 MHz) 2.40 (s, 3H), 7 00 (t, 1 H), 7 38 (t, 1 H), 7 40-7 50 (m, 3H), 7 65 (d, 2H), 7.90 (d, 2H), 7.96 (s, 1H), 8.05 (d, 1H), 8.16 (d, I H), 9.65 (s. 1H), 1 1.50 (bs) METHOD OF TREATMENT The compounds of Formula (I), and (II), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages, or other chemokines which bind to the IL-8 a or b receptor, also referred to as the type I or type II receptor Accordingly, the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (I), or (II), or a pharmaceutically acceptable salt thereof In particular, the chemokines ars IL-8. GROa. GROb. GROg, ENA-78 or NAP-2 For purposes herein, compounds of Formula (I) and/or (II), will be referred to as "compounds of Formula (I)" The compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine function, m particular IL-8, GROα. GROβ, GROγ, ENA-78 or NAP-2 , such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state Abnormal levels of IL-8, GROα, GROβ, GROγ, ENA-78 or NAP-2 for instance m the context of the present invention, constitute: (0 levels of free IL-8 greater than or equal to 1 picogram per mL. (n) any cell associated IL-8, GROα, GROβ, GROγ, ENA-78 or NAP-2 above normal physiological levels, or (ιn)the presence of IL-8, GROα. GROβ, GROγ, ENA-78 or NAP-2 above basal levels in cells or tissues in which IL-8. GROα. GROβ, GROγ, ENA-78 or NAP-2 respectively, is produced There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and or causing the disease Chemokine mediated diseases include psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephπtis. thrombosis, graft vs. host reaction, alzheimers disease, allograft rejections, malaria, restinosis. angiogenesis or undesired hematopoietic stem cells release. These diseases are primarily characterized by massive neutrophil infiltration. T-cell infiltration, or neovascular growth, and are associated with increased IL-8, GROα, GROβ, GROγ, or NAP-2 production which is responsible for the chemotaxis of neutrophils into the inflammatory site or the directional growth of endothelial cells. In contrast to other inflammatory cytokines (IL-1 , TNF, and IL- 6), IL-8, GROα, GROβ, GROγ, or NAP-2 has the unique property of promoting neutrophil chemotaxis, enzyme release including but not limited to elastase release as well as superoxide production and activation The a-chemokines but particularly GROα, GROβ, GROγ, or NAP-2, working through the IL-8 type I or II receptor can promote the neovasculaπzation of tumors by promoting the directional growth of endothelial cells. Therefore, the inhibition of IL-8 induced chemotaxis or activation would lead to a direct reduction in the neutrophil infiltration. Recent evidence also implicates the role of chemokines in the treatment of HIV infections, Littleman et a!., Nature 381 , pp661 ( 1996) and Koup et al , Nature 381 , pp 667 ( 1996) The present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I). CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region Also included within this definition is ischemic stroke. particularly to the brain area. Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, u.sually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel. The role of inflammatory cytokines in this are has been emerging and the present invention provides a mean for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as tnese has been available. TNF-a is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression. Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury. See Liu et al , Stoke, Vol. 25., No. 7, pp 1481-88 ( 1994) whose disclosure is incorporated herein by reference. 22- SUBST1TUTE SHEET (RULE 26) Models of closed head injuries and treatment with mixed 5-LO/CO agents is discussed in Shohami et al . J of Vaisc & Clinical Physiology and Pharmacology, Vol. 3, No 2, pp 99- 107 ( 1992) whose disclosure is incorporated herein by reference Treatment which reduced edema formation was found to improve functional outcome in those animals treated The compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8, binding to the IL-8 alpha or beta receptors, from binding to these receptors such as evidenced by a reduction in neutrophil chemotaxis and activation The discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the in vitro receptor binding assays which are described herein The compounds of Formula (I) have been shown, in some instances, to be dual inhibitors of both recombinant type I and type II IL-8 receptors Preferably the compounds are inhibitors of only one receptor, more preferably Tv pe II As used herein, the term "IL-8 mediated disease or disease state" refers to any and all disease states in which IL-8. GROα GROβ. GROγ, ENA-78 or NAP-2 plays a role, either by production of IL-8, GROα. GROβ. GROγ, ENA-78 or NAP-2 themselves, or by IL-8 GROα. GROβ. GROγ. ENA-78 or NAP-2 causing another monokine to be released, such as but not limited to IL- 1 IL-6 or TNF A disease state in which, tor instance. IL- 1 is a major component and whose production or action, is exacerbated or secreted in response to IL-8 would therefore be considered a disease stated mediated by IL-8 As used herein, the term "chemokine mediated disease or disease state" refers to any and all disease states in which a chemokine which binds to an IL-8 a or b receptor plays a role, such as but not limited to IL 8 GROα. GROβ, GROγ, ENA-78, or NAP-2 This would include a disease state in which. IL-8 plays a role, either by production of IL-8 itself, or by IL-8 causing another monokine to be released, such as but not limited to IL- 1 , IL-6 or TNF A disease state in which, for instance, IL- 1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8 As used herein, the term "cytokine ' refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response A cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear ceil, such as a macrophage and/or monocyte Many other cells however also produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes and B-lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to. Interleukιn-1 (IL-1), Interleukιn-6 (IL-6), Interleukιn-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-α) and Tumor Necrosis Factor beta (TNF-β) As used herein, the term "chemokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term "cytokine" above A chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils. monocytcs. macrophages, T-cells. B-cclls. endothelial cells and smooth muscle cells Examples of chemokines include, but are not limited to, IL-8 GROα. GROβ. GROγ. ENA-78, NAP-2, IP- 10, MlP-l . MlP-b, PF4, and MCP 1. 2. and 3 In order to use a compound of Formula (I), or (II), or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non-toxic amount of a compound of Formula (I) or (II) and a pharmaceutically acceptable carrier or diluent Compounds of Formula (I) or (II), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrιer(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, steaπc acid and the like. Exemplary of liquid carriers are syrup, peanut oil. olive oil, water and the like Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax. A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge The amount of solid earner will vary widely but preferably will be from about 25mg. to about Ig When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension Compounds of Formula (I) or (II) may be administered topically, that is by non-systemic administration This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear. eye and nose, such that the compound does not significantly enter the blood stream In contrast, systemic administration refers to oral, intravenous, intrapeπtoneal and intramuscular administration. Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the Formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w. more preferably from 0 1% to 1% w/w of the Formulation. Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous - 25- SUBSTJTUTE SHEET (RULE 26) solution optionally containing a bacteπcide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil Creams, ointments or pastes according to the present invention are semi- solid formulations of the active ingredient for external application They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap, a mucilage, an oil of natural origin such as almond, corn, arachis, castor or olive oil. wool fat or its derivatives oi a fatty acid such as steπc or olcic acid together with an alcohol such as propylene glycol or a macrogel The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as si caceous silicas, and other ingredients such as lanolin, may also be included Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 C. for halt an hour Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuπc nitrate or acetate (0.002%), benzalkonium chloride (0 01 %) and chlorhexidine acetate (0.01 %) Suitable solvents for the preparation of an oily solution include glycerol. diluted alcohol and propylene glycol Compounds of Formula (I) or (II), may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or mtrapeπtoneal administration The subcutaneous and intramuscular forms of - 26- SUBST1TUTE SHEET (RULE 26) parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques For all methods of use disclosed herein for the compounds of Formula (I), or (II), the daily oral dosage regimen will preferably be from about 0 01 to about 80 mg/kg of total body weight. The daily parenteral dosage regimen about 0.001 to about 80 mg/kg of total body weight. The daily topical dosage regimen will preferably be from 0 1 mg to 150 mg, administered one to four, preferably two or three times daily The daily inhalation dosage regimen will preferably be from about 0 01 mg/kg to about I mg/kg per day It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula ( I) or ( II ). or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal coui se of treatment, i.e . the number of doses of a compound of Formula (I ) or ( II). or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests The invention will now be described by reference to the following biological examples which are merely illustrative and are not lo be construed as a limitation of the scope of the present invention. BIOLOGICAL EXAMPLES The IL-8. and Gro-a chemokine inhibitiory ef fects of compounds of the present invention were determined by the following in vitro assay- Receptor Binding Assays: [ --" • -"I] iL-8 (human recombinant) is obtained from Amersham Corp , Arlington Heights, IL, with specific activity 2000 Ci/mmol. Gro-a is obtained from NEN- New England Nuclear. All other chemicals are of analytical grade. High levels of recombinant human IL-8 type a and b receptors are individually expressed - 27- SUBS UTE SHEET (RULE 26) in Chinese hamster ovary cells as described previously (Holmes, et al., Science, 1991, 253, 1278) The Chinese hamster ovary membranes are homogenized according to a previously described protocol (Haour, et al , J Biol Chem., 249 pp 2195-2205 ( 1974)) Except that the homogenization buffer is changed to lOmM Tπs-HCL, ImM MgS04, 0.5mM EDTA (ethylene-diammetetra-acetic acid), ImMPMSF (a-toluenesulphonyl fluoride), 0 5 mg/L Leupeptin, pH 7 5 Membrane protein concentration is determined using Pierce Co micro-assay kit using bovine serum albumin as a standard All assays are performed in a 96-well micro plate format Each reaction mixture contains 125j L_g (Q 25 nM) or '-^1 Gro-a and 0 5 μg/mL of IL-8Ra or 1 0 μg/mL of IL-8Rb membranes in 20 mM Bis-Tπspropane and 0 4 mM Tπs HC1 buffers. pH 8.0, containing 1 2 mM MgSO 0 1 mM EDTA, 25 mM NaCl and 0 03% CHAPS In addition, drug or compound of interest is added which have been pre-dissolved in DMSO so as to reach a final concentration of between O Ol nM and 100 uM The assay is initiated by addition of ^-^ -lL-S After 1 hour at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber ltermat blocked with 1% polyethylenιmιne/0 5% BSA and washed 3 times with 25 mM NaCl. 10 mM TπsHCl, 1 mM MgSθ4, 0 5 mM EDTA. 0 03 % CHAPS, pH 7 4 The filter is then dried and counted on the Betaplate liquid scintillation counter The recombinant IL-8 Ra, or Type I. receptor is also referred to herein as the non-permissive receptor and the recombinant IL-8 Rb, or Type II, receptor is referred to as the permissive receptor A representative compound of Formula (I), Example 1 has been found to be active in this assay Chemotaxis Assay The in vitro inhibitory properties of these compounds are determined in the neutrophil chemotaxis assay as described in Current Protocols in Immunology, vol I, Suppl 1 , Unit 6 12.3 , whose disclosure is incorporated herein by reference in its entirety Neutrophils where isolated from human blood as described in Current Protocols in Immunology Vol I. Suppl 1 Unit 7.23 1 , whose disclosure is incorporated herein by reference in its entirety The chcmoattractants IL-8, GRO-a, GRO-b, GRO-g and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0 1 and 100 nM. The two chambers are separated by a 5um polycarbonate filter When compounds of this invention are tested, they are mixed with the cells (0.001 - 1000 nM) just prior to the addition of the cells to the upper chamber. Incubation is - 28- SUBST1TUTE SHEET (RULE 26) allowed to proceed for between about 45 and 90 mm at about 37°C in a humidified incubator with 5% CO2 At the end of the incubation period, the polycarbonate membrane is removed and the top side washed, the membrane then stained using the Diff Quick staining protocol (Baxter Products, McGaw Park, IL, USA) Cells which have chemotaxed to the chemokine are visually counted using a microscope Generally, four fields are counted for each sample, these numbers are averaged to give the average number of cells which had migrated Each sample is tested in triplicate and each compound repeated at least four times To certain cells (positive control cells) no compound is added, these cells represent the maximum chemotactic response of the cells In the case where a negative control (unstimulated) is desired, no chemokine is added to the bottom chamber The difference between the positive control and the negative control represents the chemotactic activity of the cells Elastase Release Assay The compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils. Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit 7 23 1 PMNs 0 88 x 10 6 cells suspended in Ringer s Solution (NaCl 1 18. KC1 4 56. NaHCO3 25, KH2PO4 1 03, Glucose 1 1 1. HEPES 5 mM, pH 7 4) are placed in each well of a 96 well plate in a volume of 50 ul To this plate is added the test compound (0 001 - 1000 nM) in a volume of 50 ul, Cytochalasin B in a volume of 50 ul (20ug/ml) and Ringers buffer in a volume of 50 ul These cells are allowed to warm (37 °C, 5% CO2. 95% RH) for 5 min before IL-8, GROa, GROb GROg or NAP-2 at a final concentration of 0 01 - 1000 nM was added The reaction is allowed to proceed for 45 min before the 96 well plate is centrifuged (800 xg 5 min) and 100 ul of the supernatant removed This suppernatant is added to a second 96 well plate followed by an artificial elastase substrate (MeOSuc-Ala-Ala-Pro-Val- AMC, Nova Biochem, La Jolla, CA) to a final concentration of 6 ug/ml dissolved in phosphate buffered saline Immediately, the plate is placed in a fluorescent 96 well plate reader (Cytofluor 2350, Millipore, Bedford, MA) and data collected at 3 mm intervals according to the method of Nakajima et al J Biol Chem 254 4027 ( 1979) The amount of Elastase released from the PMNs is calculated by measuring the rate of MeOSuc-Ala-Ala-Pro-Val-AMC degradation TNF-a in Traumatic Brain Injury Assay The present assay provides for examination of the expression of tumor necrosis factor mRNA in specfic brain regions which follow experimentally induced - 29- SUBSTTTUTE SHEET (RULE 26) lateral fluid-percussion traumatic brain injury (TBI) in rats Adult Sprague-Dawley rats (n=42) were anesthetized with sodium pentobarbital (60 mg/kg, 1 p ) and subjected to lateral fluid-percussion brain injury of moderate severity (2 4 atm ) centered over the left temporapaπetal cortex (n= 18). or sham" treatment (anesthesia and surgery without injury, n= 18) Animals are sacrificed by decapitation at 1 , 6 and 24 hr post injury, brains removed, and tissue samples of left (injured) parietal cortex (LC). corresponding area in the contralateral right cortex (RC), cortex adjacent to injured parietal cortex (LA), corresponding adjacent area in the right cortex (RA). left hippocampus (LH) and right hippocampus (RH) are prepared Total RNA was isolated and Northern blot hybridization is performed and quantitated relative to an TNF-a positive control RNA (macrophage = 100%) A marked increase of TNF- a mRNA expression is observed in LH ( 104±17% of positive control. p < 0 05 compared with sham ) LC ( 105±2 1 % p< 0 05) and LA (69±8% p < 0 01 ) in the traumatized hemisphere 1 hr following injury An increased TNF- a mRNA expression is also observed in LH (46±8%, p < 0 05), LC (30±3% p < 0 01 ) and LA (32±3%, p < 0 0l ) at 6 hr which resolves by 24 hr following injury In the contralateral hemisphere, expression of TNF- a mRNA is increased in RH (46+2%, p < 0 01 ). RC (4±3%) and RA (22±8%) at 1 hr and in RH (28± 1 1 % ), RC (7±5%) and RA (26±6%, p < 0 05) at 6 hr but not at 24 hr following injury In sham ( surgery without injury) or naive animals, no consistent changes in expression of TNF- a mRNA are observed in any of the 6 brain areas in either hemisphere at any times These results indicate that following parasagittal fluid-percussion brain injury, the temporal expression of TNF-a mRNA is altered in specific brain regions, including those of the non-traumatized hemisphere Since TNF- a is able to induce nerve growth factor (NGF) and stimulate the release of other cvtokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF-a plays an important role in both the acute and regenerative response to CNS trauma CNS Iniurv model for IL-b mRNA This assay characterizes the regional expression of interleukin- l B (IL-1B) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats Adult Sprague-Dawley rats (n=42) are anesthetized with sodium pentobarbital (60 mg/kg, i p ) and subjected to lateral fluid-percussion brain injury of moderate severity (2 4 atm ) centered over the left temporapaπetal cortex (n=18), or "sham" treatment (anesthesia and surgery without injury) Animals are sacrificed at 1 , 6 and 24 hr post injury, brains removed, and - 30- SUBST.TUTE SHEET (RULE 26) tissue samples of left (injured) parietal cortex (LC), corresponding area in the contralateral right cortex (RC), cortex adjacent to injured parietal cortex (LA), corresponding adjacent area in the right cortex (RA), left hippocampus (LH) and right hippocampus (RH) are prepared Total RNA is isolated and Northern blot hybridization was performed and the quantity of brain tissue IL- lβ mRNA is presented as percent relative radioactivity of IL- l β positive macrophage RNA which was loaded on same gel At 1 hr following brain injury, a marked and significant increase in expression of IL- 1 β mRNA is observed in LC (20 O±O 7% of positive control. n=6, p < 0 05 compared with sham animal). LH (24 5±0 9%, p < 0 05) and LA (21 5±3 1 %, p < 0 05) in the injured hemisphere which remained elevated up to 6 hr post injury in the LC (4 O±O 4%, n=6, p < 0 05) and LH (5 O±l 3%, p < 0 05) In sham or naive animals, no expression of IL- 1 β mRNA is observed in any of the respective brain areas These results indicate that following TBI. the temporal expression of IL- l β mRNA is regionally stimulated in specific brain regions These regional changes in cytokines. such as IL- lβ play a role in the post-traumatic The above description fully discloses the invention including preferred embodiments thereof Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the f ollowing claims Without further elaboration it is believed that one skilled in the are can. using the preceding description, utilize the present invention to its fullest extent Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way The embodiments of the invention in which an exclusive property or privilege is claimed are def ined as follows - 31- SUBSJ JTUTE SHEET (RULE 26)

Claims: What is claimed is: 1 A method of treating a chemokine mediated disease state, wherein the chemokine binds to an IL-8 a or b receptor in a mammal, which comprises administering to said mammal an effective amount of a compound of the formula: W-N — (CR 13 R 14 )v — R 20 H (I) wherein X is oxygen or sulfur. Rl is independently selected from hydrogen; halogen, nitro; cyano. halosubstituted Ci-io alkyl; Ci-io alkyl: C2-10 alkenyl; C\-\Q alkoxy; halosubstituted Cj-io alkoxy; azide; (CR 8 Rg)q S(O) t R 4 , hydroxy; hydroxy C|_4alkyl, (CRgRg)q OR4: aryl; aryl C]-4 alkyl: aryloxy; aryl Ci-4 alkyloxy, heteroaryl. heteroarylalkyl; heterocyclic. heterocyclic Ci-4alkyl. heteroaryl C]-4 alkyloxy; aryl C2-10 alkenyl; heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl; (CRgR 8 )qNR4R5; C2-10 alkenyl C(O ) NR4R5, (CRgRg)q C(O ) NR4R5; (CR 8 R 8 )q C(O)NR 4 Rlθ; S(O)3R8; (CR 8 Rg)qC(O)Ri 1, C2-10 alkenylC(O)Riι,C2-10alkenylC(O)ORn,(CR 8 R 8 )qC(O)ORi2, (CRgRg)qOC(O)Rι 1; (CR 8 R 8 )qNR4C(O)Rl 1, (CRgRg)qNHS(0) 2 Ri9. (CRgRg)q S(O) NR 4 R 5 ; (CRgR 8 )qC(NR 4 )NR 4 R 5 . (CRgR 8 )qNR 4 C(NR 5 )R 1 -, or two Rl moieties together may form 0-(CH 2 ) O- or a 5 to 6 membered saturated or unsaturated ring; and wherein the aryl, heteroaryl, and heterocyclic containing moieties may be optionally substituted, q is 0, or an integer having a value of 1 to 10, t is 0, or an integer having a value of 1 or 2, s is an integer having a value of 1 to 3, v is 0 or an integer having a value of 1 to 4; m is an integer having a value of 1 to 3; n is an integer having a value of 1 to 3; R4 and R5 are independently hydrogen, optionally substituted Cj-4 alkyl, optionally substituted aryl, optionally substituted aryl Cι_4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl Ci-4alkyl, heterocyclic, heterocyclic -32- SUBST1TUTE SHEET (RULE 26) Ci-4 alkyl, or R 4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from ON/S, Y is independently selected Irom hydrogen, halogen, nitro, cyano. halosubstituted Ci-io alkyl. Ci-io alkyl. C2-10 alkenyl, Ci-io alkoxy, halosubstituted Cj-io alkoxv. azide, (CRgRg)q S(O)tR4, hydroxy. hydroxyCi- 4 alkyl, aryl, aryl Cj_4 alkyl. aryloxy. arylCj-4 alkyloxy, heteroaryl. heteroarylalkyl, heteroaryl Ci- 4 alkyloxy. heterocyclic. heterocyclic Ci- alkyl. aryl C2-10 alkenyl, heteroaryl C2-10 alkenyl, heterocyclic C2-10 alkenyl. (CRgRg)q NR4R5, C2-10 alkenyl C(O)NR R5, (CRgRg)q C ( O)NR 4 R5, (CR 8 R 8 )q C(O)NR 4 RlO, S(O)3R8, (CRgRg)q C(0)R 11 C2- 10 alkenyl C(O)R n. C2-1O alkenyl C(O)OR \ \ , C(O)Rι 1, (CR 8 Rg)q C(0)OR ]2 , (CR 8 R 8 )q OC(O) R] 1, (CRgR 8 )q NR4C(O)Rn, (CRgRg)q NHS(0) 2 R d , (CRgR 8 )q S(O) 2 NR 4 R 5 , (CRgRg)qC(NR 4 )NR 4 R (CRgR 8 )q NR 4 C(NR )Rι 1 or two Y moieties together may form 0-(CH 2 )sO- or a 5 to 6 membered saturated or unsaturated ring, wherein the aryl heteroaryl, and heterocyclic containing moieties may be optionally substituted R6 and R7 are independently hydrogen or a Ci- 4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, R is independently selected from hydrogen or Cι_ 4 alkyl, RlO is Cj-io alkyl C(0)2R8- Rl 1 is hydrogen, optionally substituted Cj- 4 alkvl, optionally substituted arvl. optionally substituted aryl Ci- alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi- 4 aIkyl optionally substituted heterocyclic, or optionally substituted heterocychcC ]-4alky I. Rl2 is hydrogen, Cl-io alkyl. optionally substituted aryl or optionally substituted arylalkyl, R 13 and R 14 are independently hydrogen, optionally substituted C 1.4 alkyl or one of R13 and R14 may be optionally substituted aryl R is NRgR7, alkyl, aryl, aryl C*_ 4 alkyl, aryl C _4 alkenyl heteroaryl. heteroaryl C * _4 alkyl, heteroarylC . alkenyl, heterocyclic. heterocyclic C*_ alkyl, heterocyclic C2-4 alkenyl. or camphor, all of which groups may be optionally substituted, R-j is NR6R7, alkyl, arylC|_4 alkyl, arylC 2 -4 alkenyl, heteroaryl, hetroarvlCj^alkyl. heteroarylC2- 4 alkenyl, heterocyclic. or heterocychcC].4 alkyl. and wherein the alkyl, aryl. heteroaryl. and heterocyclic containing rings may be optionally substituted, Rl9 is suitably C j-4 alkyl. aryl, aryl C i -4alkyl, heteroaryl, heteroarylC [- 4 alkyl, heterocyclic, or heterocychcC i- 4 alkyl, and wherein the all of these moieties may be optionally substituted. R 20 ι W , , the E containing ring is optionally selected Irom the asteπx denoting point of attachment ot the ring, the E' containing ring is optionally selected from the ring, or a pharmaceutically acceptable salt thereof 2. The method according to Claim 1 wherein Rl is substituted in the 3-positιon, the 4- position or di substituted in the 3,4- position by an electron withdrawing moiety. 3. The method according to Claim 1 wherein R * is halogen, cyano, nitro. CF3, C(O)NR4R5, alkenyl C(0)NR 4 Rs, C(O) R4R 10, alkenyl C(O)ORi2, heteroaryl, heteroarylalkyl , heteroaryl alkenyl, or S(O)NR 4 R5- 4 The method according to Claim 1 wherein Y is halogen, Cj-4 alkoxy, optionally substituted aryl. optionally substituted arylalkoxy, methylene dioxy, NR4R5, thιoCj-4alkyl. thioaryl, halosubstituted alkoxy, optionally substituted Cj - 4alkyl. hydroxy alkyl 5 The method according to Claim 1 wherein R * -, is an optionally substituted aryl or arylalkyl moiety 6 The method according to Claim 1 wherein R Q is an optionally substituted phenyl 7 The method according to any of Claims I to 6 wherein the mammal is afflicted with a chemokine mediated disease selected from psoriasis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease. Crohn's disease, ulcerative colitis. septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephπtis. thrombosis, aizheimers disease, graft vs. host reaction, or allograft rejections 8. A compound of the formula: wherein X is oxygen or sulfur; R is C(O)NHS(O) m R b ; Rl is independently selected from hydrogen; halogen; nitro; cyano: halosubstituted Ci-io alkyl; Ci-io alkyl: C 2 -10 alkenyl; Ci-io alkoxy; halosubstituted Ci-io alkoxy; azide; (CR 8 R 8 )q S(O) t R ; hydroxy; hydroxy Ci-4alkyl; (CR 8 R )q OR 4 ; aryl; aryl -4 alkyl: aryloxy; aryl C]. alkyloxy; heteroaryl; heteroarylalkyl; heterocyclic, heterocyclic Ci- alkyl: heteroaryl Cj-4 alkyloxy; aryl C2-10 alkenyl; heteroaryl C2-10 alkenyl; heterocyclic C2-10 alkenyl; (CR 8 R 8 )qNR4R5; C2-10 alkenyl C(O)NR4R5: (CR 8 R 8 )q C(0)NR4Rs; (CR 8 R 8 )q C(O)NR 4 Rlθ; S(O)3R8; (CR 8 R 8 )qC(O)Rl l; C 2 -10 alkenylC(O)Rn; C2-10alkenylC(O)ORH; (CR 8 R 8 )qC(O)ORi2; (CR 8 R 8 )qOC(O)Ri 1; (CR 8 R 8 )qNR4C(O)Rι 1; (CR 8 R 8 )qNHS(O) 2 R 19 ; (CR 8 R 8 )q S(O) 2 NR 4 R 5 : (CR 8 R 8 )qC(NR 4 )NR 4 R 5 ; (CR 8 R )qNR4C(NR5)Rι j; or two Ri moieties together may form O-(CH 2 ) s O- or a 5 to 6 membered saturated or unsaturated ring; and wherein the aryl, heteroaryl, and heterocyclic containing moieties may be optionally substituted; q is 0, or an integer having a value of 1 to 10; t is 0, or an integer having a value of 1 or 2; s is an integer having a value of 1 to 3; v is 0 or an integer having a value of 1 to 4; m is an integer having a value of 1 to 3; n is an integer having a value of 1 to 3; R4 and R5 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl. optionally substituted heteroaryl Cι_4alkyl, heterocyclic, heterocyclic Cj-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S; Y is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted Ci-io alkyl; Cl-io alkyl; C2-10 alkenyl; Ci-io alkoxy; halosubstituted Ci-io alkoxy; azide; (CR R 8 )q S(O)tR4; hydroxy; hydroxyC]-4alkyl; aryl; aryl -4 alkyl: aryloxy; arylCi-4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl Ci- 4 alkyloxy; heterocyclic. heterocyclic Cι_ 4 alkyl; aryl C 2 _10 alkenyl; heteroaryl C2-10 alkenyl; heterocyclic C2-10 alkenyl; (CR Rg)q NR4R5; C2-10 alkenyl C(O)NR4R 5 ; (CR 8 R 8 )q C(O)NR 4 R5; (CR 8 R 8 )q C(O)NR4Rlθ; S(O)3R8; (CR 8 R 8 )q C(O)R 11; C2-I0 alkenyl C(O)R 11; C2-10 alkenyl C(O)OR 11 ; C(O)Rn; (CR 8 R 8 )q C(O)ORι 2 ; (CR 8 R 8 )q OC(O) Rn; (CR 8 R 8 )q NR4C(O)R t 1; (CR 8 R8)q NHS(O) 2 R d ; (CR 8 R 8 )q S(O) 2 NR 4 R 5 ; (CR 8 R 8 )qC(NR 4 )NR R5, (CR 8 R 8 )q NR 4 C(NR5)R * \ or two Y moieties together may form O-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring; wherein the aryl, heteroaryl, and heterocyclic containing moieites may be optionally substituted, R6 and R7 are independently hydrogen or a C 1 -4 alkyl group; or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, R is independently selected from hydrogen or C 1-4 alkyl; Rio is C j- io alkyl C(O)2R8, Rl 1 is hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl C l -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocyclic, or optionally substituted heterocychcC i- 4 alkyl, R 12 is hydrogen, C i- io alkyl, optionally substituted aryl or optionally substituted arylalkyl, Rl3 and R14 are independently hydrogen, optionally substituted C ι _ 4 alkyl or one of R13 and R 14 may be optionally substituted aryl, Rb is NRgRγ, alkyl, aryl, aryl Cι _ 4 alkyl, aryl C 2 . 4 alkenyl, heteroaryl, heteroaryl C [ _ 4 alkyl, heteroarylC . 4 alkenyl. heterocyclic, heterocyclic C 1.4 alkyl, heterocyclic C 2 _4 alkenyl, or camphor, all of which groups may be optionally substituted, Rr] is NRgRγ, alkyl, arylC ι _4 alkyl, arylC 9.4 alkenyl, heteroaryl, hetroarylC ι _4alkyl, heteroarylC 2 _4 alkenyl, heterocyclic, or heterocychcC 1.4 alkyl, and wherein the alkyl. aryl, heteroaryl, and heterocyclic containing rings may be optionally substituted; Rl9 is suitably C i -4 alkyl, aryl, aryl C i -4alkyl, heteroaryl, heteroarylC i -4alkyl, heterocyclic, or heterocychcC ι_4alkyl, and wherein the all of these moieties may be optionally substituted; 37- the E containing ring is optionally selected from the asterix * denoting point of attachment of the ring, the E' containing ring is optionally selected from the ring, or a pharmaceutically acceptable salt thereof. 9. The compound according to Claim 8 wherein R [ is halogen, cyano, nitro, CF3, C(O)NR4R5, alkenyl C(O)NR4R5, C(O) R4 1O. alkenyl C(O)ORj , heteroaryl, heteroarylalkyl, heteroaryl alkenyl, or S(O)NR4R5. 10. The compound according to Claim 8 wherein Y is halogen, C1-4 alkoxy, optionally substituted aryl, optionally substituted arylalkoxy, methylene dioxy. NR4R5, thioCi-4alkyl, thioaryl, halosubstituted alkoxy, optionally substituted Ci-4alkyl, hydroxy alkyl. 38- 11 The compound according to Claim 8 wherein R 1 is substituted in the 3- posmon, the 4- position or di substituted in the 3,4- position by an electron withdrawing moiety 12 The compound according to Claim 8 wherein R b is an optionally substituted aryl, or arylalkyl moiety 13 The compound according to Claim 9 wherein R Q IS an optionally substituted phenyl 14 A pharmaceutical composition comprising an effective amount of a compound according to any of Claims 8 to 13, and a pharmaceutically acceptable carrier or diluent 15 A compound of the formula W-N , N— ( CR 13 R 14 ) V — R 20 (I) wherein X is oxygen or sulfur, R is C(O)NHS(O) m R , Rl is independently selected from hydrogen; halogen, nitro. cyano. halosubstituted Ci-io alkyl, Ci-io alkyl; C _ιo alkenyl, C|_io alkoxy; halosubstituted Cj-io alkoxy, azide, (CR 8 R )q S(O) t R4; hydroxy, hydroxy C]-4alkyl, (CR 8 R )q OR4; aryl; aryl Cj-4 alkyl, aryloxy; aryl Ci- 4 alkyloxy, heteroaryl, heteroarylalkyl, heterocyclic, heterocyclic Ci- 4 alkyl, heteroaryl Ci- 4 alkyloxy; aryl C -io alkenyl, heteroaryl C 2 -10 alkenyl, heterocyclic C 2 -10 alkenyl; (CR 8 R 8 )qNR 4 R5; C 2 -10 alkenyl C(O)NR 4 R5. (CR 8 R 8 )q C(O)NR 4 R5; (CR 8 R 8 )q C(O)NR4RlO, S(O)3R8; (CR 8 R 8 )qC(O)Ri j , C2-10 alkenylC(O)Rι 1; C2-10alkenylC(O)ORι 1, (CR 8 R 8 )qC(O)ORi2, (CR 8 R 8 )qOC(O)Rι 1; (CR 8 R 8 )qNR 4 C(O)Ri l; (CR 8 R 8 )qNHS(O) 2 R 19 , (CR 8 R 8 )q S(O) 2 NR 4 R 5 ; (CR 8 R 8 )qC(NR 4 )NR 4 R 5 , (CR 8 R )qNR4C(NR5)R j j ; or two Rl moieties together may form O-(CH ) s O- 39- or a 5 to 6 membered saturated or unsaturated ring; and wherein the aryl, heteroaryl, and heterocyclic containing moieties may be optionally substituted; q is 0, or an integer having a value of 1 to 10; t is 0, or an integer having a value of 1 or 2; s is an integer having a value of 1 to 3; v is 0 or an integer having a value of 1 to 4; m is an integer having a value of 1 to 3; n is an integer having a value of 1 to 3; R4 and R5 are independently hydrogen, optionally substituted C i-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci- 4 alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C i-4alkyl, heterocyclic, heterocyclic C 1-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S; R6 and R7 are independently hydrogen or a C i-4 alkyl group; or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R 8 is independently selected from hydrogen or C 1 -4 alkyl; R io is C i-10 alkyl C(O)2R8; Rl 1 is hydrogen, optionally substituted C1 -4 alkyl, optionally substituted aryl, optionally substituted aryl C ] -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i -4alkyl, optionally substituted heterocyclic, or optionally substituted heterocychcC ι _ 4 alkyl; R12 is hydrogen, C ι_ 10 alkyl, optionally substituted aryl or optionally substituted arylalkyl; R * 3 and Rj 4 are independently hydrogen, optionally substituted Cι_4 alkyl or one of R13 and R j 4 may be optionally substituted aryl; R * 3 is NRgR7, alkyl, aryl, aryl C j . alkyl, aryl C 2 _ 4 alkenyl, heteroaryl, heteroaryl C * _4 alkyl, heteroarylC 2 _4 alkenyl, heterocyclic, heterocyclic C1.4 alkyl, heterocyclic C . 4 alkenyl, or camphor, wherein the arlkyl, aryl, heteroaryl, and heterocyclic ring containing groups may be optionally substituted; Rl9 is suitably Ci-4 alkyl, aryl, aryl C i-4alkyl, heteroaryl, heteroarylC i-4_dkyl, heterocyclic, or heterocyclicC i_ 4 alkyl, and wherein the all of these moieties may be optionally substituted; R 2 0 is an optionally substituted heteroaryl, optionally substituted C5_ 8 cycloalkyl, optionally substituted C \.\Q alkyl, optionally substituted C 2 _ IQ alkenyl, or an optionally substituted C 2 -io alkynyl; the E containing ring is optionally selected from the asterix * denoting point of attachment of the ring; the E' containing ring is optionally selected from the ring, or a pharmaceutically acceptable salt thereof. 16. The compound according to Claim 15 wherein Rl is halogen, cyano, nitro, CF3, C(O)NR4R5, alkenyl C(O)NR 4 R5, C(O) R4R10, alkenyl C(O)ORi 2 , heteroaryl, heteroarylalkyl , heteroaryl alkenyl, or S(O)NR4R5. 17. The compound according to Claim 15 wherein Y is halogen, Ci-4 alkoxy, optionally substituted aryl, optionally substituted arylalkoxy, methylene dioxy, 41- NR4R5, thιoCi-4alkyI, thioaryl, halosubstituted alkoxy, optionally substituted Cl- alkyl, hydroxy alkyl. 18 The compound according to Claim 15 wherein Ri is substituted in the 3- position, the 4- position or di substituted in the 3,4- position by an electron withdrawing moiety. 19 The compound according to Claim 15 wherein R j is an optionally substituted aryl, or arylalkyl moiety 20 The compound according to Claim 15 wherein R rj is an optionally substituted heteoaryl 21 A pharmaceutical composition comprising an effective amount of a compound according to any of Claims 15 to 21, and a pharmaceutically acceptable carrier or diluent 22 A method of treating a chemokine mediated disease state, wherein the chemokine binds to an IL-8 a or b receptor in a mammal, which comprises administering to said mammal an effective amount of a compound according to any of Claims 15 to 20. 23 The method according to Claims 22 wherein the mammal is afflicted with a chemokine mediated disease selected from psoriasis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephπtis, thrombosis, alzheimers disease, graft vs. host reaction, or allograft rejections. - 42-

Inventors: XIANG JIA-NING, XIANG, JIA-NING
Applicants: SMITHKLINE BEECHAM CORP, XIANG JIA NING, SMITHKLINE BEECHAM CORPORATION, XIANG, JIA-NING
Application year: 1997
Main classification: A61K31
IPC codes: A61K31, A61P37, C07C311